                         SEQUENCE LISTING

<110>  Consejo Superior de Investigaciones Cientficas (CSIC)
       Instituto de Salud Carlos III (ISCIII)
 
<120>  THERAPEUTIC TARGET AND MONOCLONAL ANTIBODIES AGAINST IT FOR THE 
       DIAGNOSIS AND TREATMENT OF ALZHEIMERS DISEASE

<130>  PCT1641.1438

<150>  EP19382105.5
<151>  2019-02-15

<160>  14    

<170>  PatentIn version 3.5

<210>  1
<211>  138
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Light chain of the variable region of the first mAb of the 
       invention (mAb 10.5.6)

<400>  1

Asp Ile Gln Met Thr Gln Thr Gln Val Phe Val Tyr Met Leu Leu Trp 
1               5                   10                  15      


Leu Ser Gly Val Asp Gly Asp Ile Val Met Thr Gln Ser Gln Lys Phe 
            20                  25                  30          


Met Ser Thr Ser Val Gly Asp Arg Val Ser Val Thr Cys Lys Ala Ser 
        35                  40                  45              


Gln Asn Val Arg Thr Asn Val Ala Trp Tyr Gln Gln Arg Pro Gly Gln 
    50                  55                  60                  


Ser Pro Lys Ala Leu Ile Tyr Ser Ala Ser Tyr Arg Tyr Ser Gly Val 
65                  70                  75                  80  


Pro Asp Arg Phe Thr Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 
                85                  90                  95      


Ile Ser Asn Val Gln Ser Glu Asp Leu Ala Lys Tyr Phe Cys Gln Gln 
            100                 105                 110         


Phe Asn Thr Phe Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile 
        115                 120                 125             


Lys Arg Ala Asp Ala Ala Pro Thr Val Ser 
    130                 135             


<210>  2
<211>  120
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain of the variable region of the first mAb of the 
       invention (mAb 10.5.6)

<400>  2

Asp Ala Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys 
1               5                   10                  15      


Ala Ser Gly Tyr Thr Phe Thr Asp His Ala Ile His Trp Val Lys Gln 
            20                  25                  30          


Lys Pro Gln Gln Gly Leu Glu Trp Ile Gly Tyr Ile Ser Pro Gly Asn 
        35                  40                  45              


Gly Asp Ile Lys Tyr Asn Glu Lys Phe Gln Gly Lys Ala Thr Leu Thr 
    50                  55                  60                  


Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Asn Ser Leu Ile 
65                  70                  75                  80  


Ser Glu Asp Ser Ala Val Tyr Phe Cys Lys Arg Tyr Gly Asn Tyr Val 
                85                  90                  95      


Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala Ala Lys Thr Thr 
            100                 105                 110         


Pro Pro Ser Asp Ser Pro Leu Ala 
        115                 120 


<210>  3
<211>  127
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Heavy chain of the variable region of the second mAb of the 
       invention (mAb 17.08.13)

<400>  3

Met Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly Phe Leu 
1               5                   10                  15      


Arg Leu Ser Cys Ala Thr Ser Gly Phe Thr Phe Thr Asp Asn Tyr Met 
            20                  25                  30          


Asn Trp Val Arg Gln Pro Pro Gly Lys Ala Leu Glu Trp Leu Gly Leu 
        35                  40                  45              


Ile Arg Asn Lys Ala Asn Gly Tyr Thr Thr Glu Tyr Ser Ala Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Gln Asn Ile Val Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Thr Leu Arg Ala Glu Asp Ser Gly Thr Tyr Phe Cys 
                85                  90                  95      


Ala Arg Ala Gly Tyr Phe Asp Asp Trp Gly Ala Gly Thr Thr Val Thr 
            100                 105                 110         


Val Ser Ser Ala Lys Thr Thr Pro Pro Ser Asp Tyr His Thr Gly 
        115                 120                 125         


<210>  4
<211>  415
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Nucleotide sequence encoding the light chain of the variable 
       region of the first mAb of the invention (mAb 10.5.6)

<400>  4
gatatccaga tgacacagac tcaggtcttt gtatacatgt tgctgtggtt gtctggtgtt       60

gatggagaca ttgtgatgac ccagtctcaa aaattcatgt ccacatcagt aggagacagg      120

gtcagcgtca cctgcaaggc cagtcagaat gtgcgtacta atgtagcctg gtatcaacag      180

agaccagggc aatctcctaa agcactgatt tactcggcat cctaccggta cagtggagtc      240

cctgatcgct tcacaggcag tggatctggg acagatttca ctctcaccat cagcaatgtg      300

cagtctgaag acttggcaaa gtatttctgt cagcaattta acacctttcc gtacacgttc      360

ggagggggga ccaagctgga aataaaacgg gctgatgctg caccaactgt atcca           415


<210>  5
<211>  368
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Nucleotide sequence encoding the heavy chain of the variable 
       region of the first mAb of the invention (mAb 10.5.6)

<400>  5
caggtgcagc tgaaggagtc tgacgctgag ttggtgaaac ctggggcttc agtgaagata       60

tcctgcaagg cttctggcta caccttcact gaccatgcta ttcactgggt gaagcagaag      120

cctcaacagg gcctggaatg gattggatat atttctcccg gaaatggtga tattaagtac      180

aatgagaagt tccagggcaa ggccacactg actgcagaca aatcctccag tactgcctac      240

atgcagctca acagcctgat atctgaggat tctgcagtgt atttctgtaa aagatatggt      300

aactacgttt actggggcca agggactctg gtcactgtct ctgcagccaa aacgacaccc      360

ccatctga                                                               368


<210>  6
<211>  369
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Nucleotide sequence encoding the heavy chain of the variable 
       region of the second mAb of the invention (mAb 17.08.13)

<400>  6
gctggtggaa tctggaggag gcttggtaca gcctgggggt tttctgagac tctcctgtgc       60

aacttctggg ttcaccttca ctgataacta catgaactgg gtccgccagc ctccaggaaa      120

ggcacttgag tggttgggtt tgattagaaa caaagctaat ggttacacaa cagagtacag      180

tgcatctgtg aagggtcggt ttaccatctc cagagataat tcccaaaaca tcgtctatct      240

tcaaatgaac accctgagag ctgaggacag tggcacttat ttctgtgcaa gagcagggta      300

cttcgatgac tggggcgcag ggaccacggt caccgtctcc tcagccaaaa cgacaccccc      360

atctgacta                                                              369


<210>  7
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  GAPDH forward primer

<400>  7
accacagtcc atgccatcac                                                   20


<210>  8
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  GAPDH reverse primer

<400>  8
tccaccaccc tgttgctgta                                                   20


<210>  9
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Axin2 forward primer

<400>  9
ctccttggag gcaagagctt c                                                 21


<210>  10
<211>  21
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Axin2 reverse primer

<400>  10
gactggccac gcagcaccgc t                                                 21


<210>  11
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  APP forward primer

<400>  11
atgtgcagaa tggaaagt                                                     18


<210>  12
<211>  18
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  APP reverse primer

<400>  12
cagcatacaa actctacc                                                     18


<210>  13
<211>  23
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Adam10 forward primer

<400>  13
gctgtgattg ctcagatatc cag                                               23


<210>  14
<211>  20
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Adam10 reverse primer

<400>  14
tctttgcact ggtcactgta                                                   20


